Phase II study of prophylactic oral administration of diltiazem for atrial fibrillation after lung resection

Phase II study of prophylactic oral administration of diltiazem for atrial fibrillation after lung resection - Prophylactic administration of diltiazem for atrial fibrillation after lung resection

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001691

Enrollment

124

Registered

2009-02-06

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation after lung resection

Interventions

Diltiazem 90mg/day from POD 1 to POD 7 Diltiazem 60mg/day from POD 8 to POD 14 Lactose 0.9g/day from POD 1 to POD 7 Lactose 0.6g/day from POD 8 to POD 14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: primary lung cancer lobectomy or pneumonectomy PS 0-2 be able to take something by mouth WBC >3000 Hb >9.5 Plt >100000 T-bil <1.5 AST, ALT <80 Cre <1.5 PaO2 >65 or SpO2 >92 informed consent

Exclusion criteria

Exclusion criteria: unstable angina pectoris, myocardial infarction or heart failure with in 3 months uncontrolled diabetes or hypertension active infection gastrointestinal bleeding diarrhea ileus chronic Af already taking diltiazem or other calcium blocker AV block more than 2nd degree sick sinus syndrome past history of severe allergy uncontrolled pleural effusion, ascites or pericardial fluid in pregnancy

Design outcomes

Primary

Measure	Time frame
Incidence of atrial fibrillation after lung resection	—

Secondary

Measure	Time frame
Degree and frequency of adverse event (hypotension, bradycardia, etc.)	—

Countries

Japan

Contacts

Public ContactYasuhiro Hida

Hokkaido University Graduate School of Medicine Department of Surgical Oncology

011-706-7714

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026